CIRSE 2023 Highlights for Ablation Fanatics

If you are like me, you spent your entire summer holiday eagerly awaiting CIRSE 2023!

We hid 5  CASCINATION "elements" in the picture above. Can you find them?

To start - a shameless plug - the AI-driven CAS-One IR has been released for 6 months, and is now in 33+ hospitals with nearly 300 patients treated. In our experience being with physicians using it, it seems that Interactive planning mode has been saving physicians time, 3D reconstructions of the liver vasculature has been making trajectories safer, and an upgraded ablated tissue segmentation has given confidence that an ablation has met the desired margin.

If you have not seen this newest version of CAS-One IR, come by our booth any time for a demonstration

Now, for the scientific congress highlights - not even mentioning the multiple posters!

Saturday September 9^th

FS 125 – New Frontiers for ablation
10:00-11:00 Auditorium 15 - Moderators: C. Koelblinger, M. Burgmans

• Intrahepatic cholangiocarcinoma - O. Akhan
• Pancreatic cancer - G. Narayanan
• Prostate cancer - G. Petralia
• Breast cancer - E. de Kerviler

CEC 165 – NSCLC management in 2023 
16:15-17:15 Auditorium 3 - Moderators: A. Veltri, J. Palussiere

• Why we need biopsies - S. Pilotto
• Surgical approaches - P. Licht
• SBRT - B. Jereczek-Fossa
• Percutaneous Ablation - H. Torp Madsen
• Ablation for Recurrences - L. Tselikas
• Trans-pulmonary chemoembolization - T. Vogel

SP 176 – Advanced IO techniques: pushing the bar in IO
17:30-18:30 Room 20 - Moderators: M. Soulen, P. Sousa

• Percutaneous CT guided ablation for lung lesions in a single tertiary unit - a 12 year cohort - O. Lewis
• Intraprocedural image fusion assessment of ablation completeness reduces local tumor progression following percutaneous liver thermal ablation - K. Verdonschot
• MR-guided stereotactic ablative radiotherapy versus percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a randomised phase 2/3 trial - F. Timmer

Sunday September 10^th 

ERT 213 - The present and future of HCC management
8:30-9:30 Auditorium 15 - Moderators: J. Nault, L. Crocetti

• EASL Guidelines: what's new since the last version - B. Sangro
• Downstaging to resection/transplantation using TARE - I. Bargellini
• The future role of systemic treatment to switch from a non-curative to a curative approach - P. Nahon

FS 223 - HCC: which patients, which tumors
10:00-11:00 Auditorium 1 - Moderators: A. Denys, F. Orsi

• Ablation: enough evidence to treat nodules > 3cm - L. Crocetti
• TACE: what can be learned from histopathological correlations - R. Klöckner
• TARE: the rebirth in HCC management - R. Salem
• Loco-regional therapies and immunotherapy in advanced HCC - N. Goldberg

ERT 224 - Applying for IR specialty status: lessons learned
10:00-11:00 Auditorium 3 - Moderators: M. Lee, P. Patel

• How we achieved specialty recognition in the US - P. Patel
• Specialty status application in Ireland - C. Cantwell
• The view from Spain - A. Madrid-Vallenilla
• Brazilian experience - J. Motta Leal Filho

• AI in IR - B. Wood
• Ablation simulation and verification systems - L. Solbiati
• Stereotactic navigation - R. Bale
• Robotics - P. Paprottka  

Monday September 11^th 

• Therapeutic algorithms for HCC - A. Vogel
• Percutaneous ablative therapies for HCC - L. Crocetti
• Endovascular treatment for HCC - P. Pereira
• Therapeutic algorithms for liver mets - D. Arnold
• Percutaneous ablative therapies for liver mets - M. Meijerink
• Endovascular treatment for liver mets - J. Ricke

• Stereotactic ablation of colorectal liver metastasis aided with intra-arterial CT (Computed Tomography) hepatic arteriography and ablation confirmation software assessment (STEREOLAB) - I. Paolucci
• Transarterial chemoembolization using Idarubicin versus Doxorubicin chemoemulsion in patients with hepatocellular carcinoma (IDADOX) - J. Choi
• COLDFIRE-III trial: perivascular and peribiliary colorectal liver metastases (0-5 cm): irreversible electroporation versus stereotactic body radiotherapy - D. Vos
• Comparison of chemotherapy combined with percutaneous electroporation and chemotherapy alone in the management of locally advanced gallbladder carcinoma (GBC) - N. Kalra

• Identifying proliferative HCC on pretreatment CT image: implication in therapeutic outcome after transarterial chemoembolization - Y. Xiao
• Prospective, multi-center study of ablation confirmation software for microwave ablation of liver lesions: effect on operator decision-making, technical success, and technique efficacy - B. Odisio
• Ultrasound vector flow imaging in the healthy femoral trajectory - M. van Helvert
• Ex vivo results of CT-guided cryoablation in porcine liver - improved thermal sensitivity using virtual monochromatic imaging derived from photon counting detector CT data sets - T. Kroencke
• Ablative margin quantified by intraprocedural CT is a stronger predictor of ablation outcomes than initial follow-up CT in colorectal liver metastasis thermal ablation - Y. Lin

 Tuesday September 12^th 

• Ablation of bone tumours: which technique, when - U. Pua
• Spine electrochemotherapy - F. Deschamps
• Combined approaches - M. Callstrom
• TACE for bone tumours - A. Ryan

• SBRT for oligometastatic lung disease - B. Jereczek-Fossa
• Designing a safe and efficacious ablation - R. Suh
• Ablation for oligometastatic lung disease - D. Filippiadis
• When the patient is a child - F. Deschamps

• AI advances in tumor ablation - N. Shaida
• Evidence and starting a new Quality Ablation program - M. Maurer
• MAVERRIC: a prospective, multicenter study on SMWA vs resection - S. Weber

Wednesday September 13^th  

• What are the indications? - C. Georgiades
• What ablation technique? - R. Grasse
• What I would like to read in the new guidelines - C. Bent
• Loco-regional therapies for RCC metastatic disease - T. Jakobs